Next Generation Sequencing

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

March 27, 2018

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

July 14, 2017

Looking Beyond Genomics: A Holistic Approach to Precision Medicine

January 11, 2017
Illumina’s NovaSeq Platform Aims for the $100 Human Genome, but is it Good Business?

Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation?

Illumina utilised their showcase at the JP Morgan Conference to announce its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the […]
March 17, 2016
Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for […]
February 2, 2016
To CRISPR or not to CRISPR?

To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing

The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of […]
January 12, 2016
Evolution Analysis: Thermo Fisher to Acquire Affymetrix

Evolution M&A Analysis: Thermo Fisher to Acquire Affymetrix for $1.3 billion

Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously […]
October 28, 2015
The Role of Metagenomic Analysis in Drug Development

The Role of Metagenomic Analysis in Drug Development

In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. […]
Contact Us